{"id":"W4379967101","doi":"10.1002/ijc.34608","title":"Efficacy and safety of lenvatinib plus pembrolizumab vs sunitinib in the East Asian subset of patients with advanced renal cell carcinoma from the <scp>CLEAR</scp> trial","year":2023,"lang":"en","type":"article","venue":"International Journal of Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Eisai Canada; Eisai","keywords":"Lenvatinib; Pembrolizumab; Sunitinib; Renal cell carcinoma; Medicine; Internal medicine; Oncology; Expanded access; Clinical trial; Immunotherapy; Cancer; Hepatocellular carcinoma; Sorafenib","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002833665,0.0006538957,0.001639262,0.0002585716,0.0002745583,0.0008509171,0.0002921091,0.0004884797,0.001914755],"category_scores_gemma":[0.001234104,0.0002239384,0.002072308,0.0003153148,0.0003153978,0.0006077332,0.0003549599,0.00158779,0.0002853963],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003724752,"about_ca_system_score_gemma":0.0005563463,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000439436,"about_ca_topic_score_gemma":0.001488499,"domain_scores_codex":[0.9992548,0.0004682561,0.00006778236,0.00008473481,0.00005182488,0.0000725936],"domain_scores_gemma":[0.9991924,0.0002251706,0.0002402501,0.00006599799,0.00004829963,0.0002278926],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8721849,0.002668062,0.03376203,0.001216963,0.007864686,0.0002097901,0.0001970641,0.001691431,0.00639178,0.0002901939,0.00280119,0.07072182],"study_design_scores_gemma":[0.5714601,0.1693465,0.2177112,0.0004082909,0.01781707,0.001459521,0.0004106057,0.005597489,0.005433366,0.001206898,0.009045843,0.000103131],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9928849,0.004484318,0.0001455196,0.0003042324,0.00008116373,0.0001931636,0.0004142162,0.00001537079,0.001477002],"genre_scores_gemma":[0.9963291,0.001498479,0.0002301459,0.000388729,0.0001022139,0.0002176452,0.0007687525,0.000006312968,0.0004585925],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002833665,"threshold_uncertainty_score":0.01498604,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02026817536859123,"score_gpt":0.2789330558825701,"score_spread":0.2586648805139788,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}